Cempra drug is effective, safe for bacterial pneumonia in trial

09/15/2011 | MedCityNews.com

A midstage trial found that Cempra Pharmaceuticals' drug candidate solithromycin is as effective as FDA-approved antibiotic levofloxacin in treating community-acquired bacterial pneumonia, but with less risk of adverse effects. The result supports further evaluation of solithromycin in a Phase III test, said Cempra official David Oldach. The drug is also expected to work against sexually transmitted diseases and Legionnaires' disease.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
National Affairs Analyst
Verisk Analytics
Jersey City, NJ
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA